{"transactions":[{"id":740070,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-13T00:42:40.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":57162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":57162,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-10","underlying":"Common stock","underlying_shares":57162},"source":{"system":"sec-edgar","filing":"0001193125-26-270002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526270002/ownership.xml","form_type":"4"}},{"id":1052964,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52700,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"derivative":{"exercise_price":6.16,"underlying":"Common Stock","underlying_shares":52700},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052963,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":185000,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052962,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":6.16,"underlying":"Common Stock","underlying_shares":17544},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052961,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":50128},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052960,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":94336},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052959,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":444815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":7.05,"underlying":"Common Stock","underlying_shares":444815},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052958,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14185,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the actions of the of the Committee and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company (\"Company Stock Options,\" and each such option, a \"Company Stock Option\") that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the Cash Amount (each, an \"In-the-Money Option\") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one CVR for each Share underlying such In-the-Money Option."}],"balance_after":0,"derivative":{"exercise_price":7.05,"underlying":"Common Stock","underlying_shares":14185},"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052957,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"other","planned":false,"acquired":false,"shares":94027,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the \"Cash Amount\"); plus (ii) one non-transferable contractual contingent value right per share (each, a \"CVR\"), without interest and subject to applicable withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the \"Cash Amount\"); plus (ii) one non-transferable contractual contingent value right per share (each, a \"CVR\"), without interest and subject to applicable withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1052956,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-29T16:30:29.000Z","date":"2025-08-29","kind":"other","planned":false,"acquired":false,"shares":153903,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the \"Cash Amount\"); plus (ii) one non-transferable contractual contingent value right per share (each, a \"CVR\"), without interest and subject to applicable withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The amount reported in Column 4 includes 108,875 restricted stock units of the Company (\"Company Restricted Stock Units,\" and each such restricted stock unit, a \"Company Restricted Stock Unit\"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the \"Committee\") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or"},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an \"Accelerated Vesting Restricted Stock Unit\") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the \"Company\"), Concentra Biosciences LLC (\"Parent\"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Parent completed a tender offer for shares of common stock of the Company (\"Shares\") and thereafter, the Merger Sub merged with and into the Company (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding Share was canceled and converted into the right to receive (i) $10.047 in cash per share (the \"Cash Amount\"); plus (ii) one non-transferable contractual contingent value right per share (each, a \"CVR\"), without interest and subject to applicable withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The amount reported in Column 4 includes 108,875 restricted stock units of the Company (\"Company Restricted Stock Units,\" and each such restricted stock unit, a \"Company Restricted Stock Unit\"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company (the \"Committee\") and in accordance with the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an \"Accelerated Vesting Restricted Stock Unit\") that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the Cash Amount and (y) one CVR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-112240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025112240/ownership.xml","form_type":"4"}},{"id":1084754,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-18T21:16:18.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of the shares subject to the option shall vest and become exercisable on August 16, 2025 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.12,"expiration_date":"2035-07-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-25-020024","document":"form4-07182025_090713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925020024/form4-07182025_090713.xml","form_type":"4"}},{"id":1115125,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":false,"shares":94027,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":3,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":94027},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115124,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":0,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115123,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":false,"shares":43883,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":94030,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":43883},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115122,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":false,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":18000,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115121,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":false,"shares":43882,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":137913,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":43882},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115120,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":false,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":26400,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115119,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":true,"shares":94027,"price":4.3,"value":404316.1,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":94027,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115118,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":4.3,"value":77400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":153903,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115117,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":43883,"price":10.02,"value":439707.66,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115116,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":true,"shares":43883,"price":4.3,"value":188696.9,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":43883,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115115,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":10.02,"value":84168.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.06, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115114,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-10","kind":"exercise","planned":true,"acquired":true,"shares":8400,"price":4.3,"value":36120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":144303,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115113,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"sale","planned":true,"acquired":false,"shares":43882,"price":10.03,"value":440136.46,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.98 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115112,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":true,"shares":43882,"price":4.3,"value":188692.6,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":43882,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115111,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":10.03,"value":84252.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.17, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1115110,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-11T21:01:31.000Z","date":"2025-06-09","kind":"exercise","planned":true,"acquired":true,"shares":8400,"price":4.3,"value":36120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":144303,"source":{"system":"sec-edgar","filing":"0000950170-25-085047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025085047/ownership.xml","form_type":"4"}},{"id":1119851,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":false,"shares":43882,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":181795,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":43882},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119850,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":false,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":34800,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119849,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":false,"shares":43882,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":225677,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":43882},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119848,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":false,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":43200,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119847,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":false,"shares":43883,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":269559,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":43883},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119846,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":false,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":51600,"derivative":{"exercise_price":4.3,"exercise_date":"2022-07-01","expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119845,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"sale","planned":true,"acquired":false,"shares":43882,"price":10.21,"value":448035.22,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.15 to $10.31, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119844,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":true,"shares":43882,"price":4.3,"value":188692.6,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":43882,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119843,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":10.21,"value":85764.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.15 to $10.31, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119842,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-06","kind":"exercise","planned":true,"acquired":true,"shares":8400,"price":4.3,"value":36120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":144303,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119841,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"sale","planned":true,"acquired":false,"shares":43882,"price":10.15,"value":445402.3,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.08 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119840,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":true,"shares":43882,"price":4.3,"value":188692.6,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":43882,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119839,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":10.15,"value":85260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.08 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119838,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-05","kind":"exercise","planned":true,"acquired":true,"shares":8400,"price":4.3,"value":36120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":144303,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119837,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"sale","planned":true,"acquired":false,"shares":43883,"price":10.1,"value":443218.3,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.21, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119836,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":true,"shares":43883,"price":4.3,"value":188696.9,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MG3A is a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":43883,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119835,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":10.1,"value":84840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.20, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1119834,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-06-06T21:03:26.000Z","date":"2025-06-04","kind":"exercise","planned":true,"acquired":true,"shares":8400,"price":4.3,"value":36120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025."}],"balance_after":144303,"source":{"system":"sec-edgar","filing":"0000950170-25-083411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025083411/ownership.xml","form_type":"4"}},{"id":1212437,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T20:00:10.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":459000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option shall vest over four years, with 25% vesting on March 7, 2026 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the issuer."}],"balance_after":459000,"derivative":{"exercise_price":7.05,"expiration_date":"2035-03-07","underlying":"Common Stock","underlying_shares":459000},"source":{"system":"sec-edgar","filing":"0000950170-25-037515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025037515/ownership.xml","form_type":"4"}},{"id":1212436,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-11T20:00:10.000Z","date":"2025-03-07","kind":"grant","planned":false,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The shares of common stock underlying the RSUs will vest over 4 years: 25% will vest on March 7, 2026 and the remainder will vest equally, on an annual basis, over the remaining 3 years, subject to the reporting person's continued service to the issuer."}],"balance_after":135903,"source":{"system":"sec-edgar","filing":"0000950170-25-037515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017025037515/ownership.xml","form_type":"4"}},{"id":1436974,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:00:02.000Z","date":"2024-08-08","kind":"gift","planned":false,"acquired":true,"shares":442800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred this stock option to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests over four years, with 25% vesting on March 7, 2025 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":442800,"derivative":{"exercise_price":11.58,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":442800},"source":{"system":"sec-edgar","filing":"0000950170-24-094990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017024094990/ownership.xml","form_type":"4"}},{"id":1436973,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:00:02.000Z","date":"2024-08-08","kind":"gift","planned":false,"acquired":false,"shares":442800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred this stock option to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests over four years, with 25% vesting on March 7, 2025 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":147600,"derivative":{"exercise_price":11.58,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":442800},"source":{"system":"sec-edgar","filing":"0000950170-24-094990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017024094990/ownership.xml","form_type":"4"}},{"id":1586966,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T19:57:57.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":590400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over four years, with 25% vesting on March 7, 2025 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":590400,"derivative":{"exercise_price":11.58,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":590400},"source":{"system":"sec-edgar","filing":"0000950170-24-028855","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017024028855/ownership.xml","form_type":"4"}},{"id":1719139,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T20:20:15.000Z","date":"2023-12-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. All of the shares of common stock underlying such RSUs will vest on December 5, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of Securities Beneficially Owned includes 1,445 and 1,195 shares purchased under the Company's 2020 Employee Stock Purchase Plan on November 30, 2022 and May 31, 2023, respectively."}],"balance_after":58903,"source":{"system":"sec-edgar","filing":"0000950170-23-068900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000095017023068900/ownership.xml","form_type":"4"}},{"id":1958945,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T19:51:36.000Z","date":"2023-03-09","kind":"gift","acquired":true,"shares":254997,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":254997,"derivative":{"exercise_price":16.66,"expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":254997},"source":{"system":"sec-edgar","filing":"0001209191-23-018013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919123018013/doc4.xml","form_type":"4"}},{"id":1958944,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T19:51:36.000Z","date":"2023-03-09","kind":"gift","acquired":false,"shares":254997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":91003,"derivative":{"exercise_price":16.66,"expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":254997},"source":{"system":"sec-edgar","filing":"0001209191-23-018013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919123018013/doc4.xml","form_type":"4"}},{"id":1958943,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T19:51:36.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":346000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":346000,"derivative":{"exercise_price":16.66,"expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":346000},"source":{"system":"sec-edgar","filing":"0001209191-23-018013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919123018013/doc4.xml","form_type":"4"}},{"id":1958941,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T19:50:52.000Z","date":"2022-04-15","kind":"gift","acquired":true,"shares":264375,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":264375,"derivative":{"exercise_price":36.21,"expiration_date":"2032-03-11","underlying":"Common Stock","underlying_shares":264375},"source":{"system":"sec-edgar","filing":"0001209191-23-018012","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919123018012/doc5.xml","form_type":"5"}},{"id":1958940,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T19:50:52.000Z","date":"2022-04-15","kind":"gift","acquired":false,"shares":264375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer."}],"balance_after":88125,"derivative":{"exercise_price":36.21,"expiration_date":"2032-03-11","underlying":"Common Stock","underlying_shares":264375},"source":{"system":"sec-edgar","filing":"0001209191-23-018012","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919123018012/doc5.xml","form_type":"5"}},{"id":2295042,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-19T19:59:48.000Z","date":"2022-04-18","kind":"exercise","acquired":false,"shares":11500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":144464,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":11500},"source":{"system":"sec-edgar","filing":"0001209191-22-024859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122024859/doc4.xml","form_type":"4"}},{"id":2295041,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-19T19:59:48.000Z","date":"2022-04-18","kind":"sale","acquired":false,"shares":33,"price":32.64,"value":1077.12,"ownership":{"direct":true},"balance_after":26263,"source":{"system":"sec-edgar","filing":"0001209191-22-024859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122024859/doc4.xml","form_type":"4"}},{"id":2295040,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-19T19:59:48.000Z","date":"2022-04-18","kind":"sale","acquired":false,"shares":11467,"price":31.87,"value":365453.29,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":26296,"source":{"system":"sec-edgar","filing":"0001209191-22-024859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122024859/doc4.xml","form_type":"4"}},{"id":2295039,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-19T19:59:48.000Z","date":"2022-04-18","kind":"exercise","acquired":true,"shares":11500,"price":4.23,"value":48645.0,"ownership":{"direct":true},"balance_after":37763,"source":{"system":"sec-edgar","filing":"0001209191-22-024859","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122024859/doc4.xml","form_type":"4"}},{"id":2321703,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-22T20:05:44.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":1548,"price":36.51,"value":56517.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.06 to $36.85, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":26263,"source":{"system":"sec-edgar","filing":"0001209191-22-020649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122020649/doc4.xml","form_type":"4"}},{"id":2321702,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-22T20:05:44.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":1159,"price":35.22,"value":40819.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.92 to $35.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":27811,"source":{"system":"sec-edgar","filing":"0001209191-22-020649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122020649/doc4.xml","form_type":"4"}},{"id":2321701,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-22T20:05:44.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":9908,"price":34.11,"value":337961.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.92 to $34.9, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":28970,"source":{"system":"sec-edgar","filing":"0001209191-22-020649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122020649/doc4.xml","form_type":"4"}},{"id":2321700,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-22T20:05:44.000Z","date":"2022-03-22","kind":"sale","acquired":false,"shares":5822,"price":33.44,"value":194687.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.88 to $33.87, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":38878,"source":{"system":"sec-edgar","filing":"0001209191-22-020649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122020649/doc4.xml","form_type":"4"}},{"id":2335658,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T19:59:36.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":352500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":352500,"derivative":{"exercise_price":36.21,"expiration_date":"2032-03-11","underlying":"Common Stock","underlying_shares":352500},"source":{"system":"sec-edgar","filing":"0001209191-22-018667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122018667/doc4.xml","form_type":"4"}},{"id":2335657,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-14T19:59:36.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying such RSUs will vest on the first anniversary of the grant date, and the remaining shares subject to the RSUs will vest on a quarterly basis thereafter in equal installments over the following twelve (12) quarters, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":44700,"source":{"system":"sec-edgar","filing":"0001209191-22-018667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122018667/doc4.xml","form_type":"4"}},{"id":2375023,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-24T20:00:25.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":544,"price":35.32,"value":19214.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.51, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":34700,"source":{"system":"sec-edgar","filing":"0001209191-22-012880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122012880/doc4.xml","form_type":"4"}},{"id":2375022,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-02-24T20:00:25.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":13956,"price":34.3,"value":478690.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.82 to $34.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":35244,"source":{"system":"sec-edgar","filing":"0001209191-22-012880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122012880/doc4.xml","form_type":"4"}},{"id":2425316,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-26T19:53:28.000Z","date":"2022-01-25","kind":"sale","acquired":false,"shares":4412,"price":36.21,"value":159758.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.75, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":49200,"source":{"system":"sec-edgar","filing":"0001209191-22-005118","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122005118/doc4.xml","form_type":"4"}},{"id":2425315,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-26T19:53:28.000Z","date":"2022-01-25","kind":"sale","acquired":false,"shares":10088,"price":35.45,"value":357619.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.91, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":53612,"source":{"system":"sec-edgar","filing":"0001209191-22-005118","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919122005118/doc4.xml","form_type":"4"}},{"id":2461260,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"exercise","acquired":false,"shares":1663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":60000,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":1663},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461259,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-21","kind":"exercise","acquired":false,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":61663,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461258,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":9111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":80889,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":9111},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461257,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":true,"shares":106200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":106200,"derivative":{"exercise_price":41.58,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":106200},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461256,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":false,"shares":106200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"One-fourth of the shares subject to the stock option will vest on March 1, 2022, subject to the reporting person's continuous service relationship with the Issuer. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":37800,"derivative":{"exercise_price":41.58,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":144000},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461255,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":true,"shares":776600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":776600,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":776600},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461254,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":false,"shares":776600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth of the shares subject to the stock option vested on July 23, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":258824,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":1035424},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461253,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":true,"shares":52700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":52700,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":52700},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461252,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":false,"shares":52700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth of the shares subject to the stock option vested on June 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":17544,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":70244},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461251,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":185000,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461250,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":false,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":155964,"derivative":{"exercise_price":4.23,"expiration_date":"2030-05-01","underlying":"Common Stock","underlying_shares":340964},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461249,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":true,"shares":313442,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By MG3A"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."}],"balance_after":313442,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":313442},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461248,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-02","kind":"gift","acquired":false,"shares":313442,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth of the shares subject to the stock option vested on January 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date."}],"balance_after":90000,"derivative":{"exercise_price":4.3,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":403442},"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461247,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":9493,"price":45.37,"value":430697.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $45.83, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":63700,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461246,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":5007,"price":44.62,"value":223412.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":73193,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461245,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":149,"price":44.92,"value":6693.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."}],"balance_after":78200,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461244,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"sale","acquired":false,"shares":1514,"price":44.31,"value":67085.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.85 to $44.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":78349,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461243,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-22","kind":"exercise","acquired":true,"shares":1663,"price":4.3,"value":7150.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."}],"balance_after":79863,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461242,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":5580,"price":45.06,"value":251434.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.825 to $45.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":78200,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461241,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":13646,"price":44.15,"value":602470.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.79, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":83780,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461240,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-21","kind":"exercise","acquired":true,"shares":19226,"price":4.3,"value":82671.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."}],"balance_after":97426,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461239,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":9111,"price":43.94,"value":400337.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.8 to $44.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":78200,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2461238,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T20:01:53.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":9111,"price":4.3,"value":39177.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."}],"balance_after":87311,"source":{"system":"sec-edgar","filing":"0001209191-21-070996","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121070996/doc4.xml","form_type":"4"}},{"id":2495602,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-24T19:59:14.000Z","date":"2021-11-22","kind":"exercise","acquired":false,"shares":16263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.45,"exercise_date":"2015-11-13","expiration_date":"2021-12-16","underlying":"Common Stock","underlying_shares":16263},"source":{"system":"sec-edgar","filing":"0001209191-21-066884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121066884/doc4.xml","form_type":"4"}},{"id":2495601,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-24T19:59:14.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":14500,"price":36.08,"value":523160.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":78200,"source":{"system":"sec-edgar","filing":"0001209191-21-066884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121066884/doc4.xml","form_type":"4"}},{"id":2495600,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-24T19:59:14.000Z","date":"2021-11-22","kind":"exercise","acquired":true,"shares":16263,"price":12.45,"value":202474.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock."}],"balance_after":92700,"source":{"system":"sec-edgar","filing":"0001209191-21-066884","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121066884/doc4.xml","form_type":"4"}},{"id":2526560,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-03T19:59:59.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":6085,"price":28.887,"value":175777.395,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.245 to $29.2, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":76437,"source":{"system":"sec-edgar","filing":"0001209191-21-062843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121062843/doc4.xml","form_type":"4"}},{"id":2526559,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-03T19:59:59.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":14391,"price":28.415,"value":408920.265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.73, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":82522,"source":{"system":"sec-edgar","filing":"0001209191-21-062843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121062843/doc4.xml","form_type":"4"}},{"id":2526558,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-03T19:59:59.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":81,"price":28,"value":2268.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."}],"balance_after":96913,"source":{"system":"sec-edgar","filing":"0001209191-21-062843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121062843/doc4.xml","form_type":"4"}},{"id":2535608,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":38789,"kind":"person","name":"Detheux Michel","position":1,"cik":"0001816196","reported_name":"Detheux Michel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-25T20:00:48.000Z","date":"2021-10-21","kind":"sale","acquired":false,"shares":196,"price":28.0001,"value":5488.0196,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.005, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":96994,"source":{"system":"sec-edgar","filing":"0001209191-21-061569","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816196/000120919121061569/doc4.xml","form_type":"4"}}],"next_cursor":"2021-10-25T20:00:48.000000Z,2535608"}